What is HC Wainwright’s Estimate for FBIO Q4 Earnings?

Fortress Biotech, Inc. (NASDAQ:FBIO) – Research analysts at HC Wainwright issued their Q4 2024 earnings per share estimates for shares of Fortress Biotech in a research note issued to investors on Monday, November 18th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will earn ($0.83) per share for the quarter. HC Wainwright has a “Buy” rating and a $26.00 price target on the stock. The consensus estimate for Fortress Biotech’s current full-year earnings is ($2.65) per share. HC Wainwright also issued estimates for Fortress Biotech’s FY2025 earnings at ($1.38) EPS, FY2026 earnings at ($1.07) EPS and FY2027 earnings at ($0.46) EPS.

Separately, StockNews.com downgraded Fortress Biotech from a “hold” rating to a “sell” rating in a research note on Friday, November 15th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to data from MarketBeat, Fortress Biotech currently has an average rating of “Moderate Buy” and an average price target of $13.67.

Fortress Biotech Stock Performance

Shares of Fortress Biotech stock opened at $1.58 on Wednesday. Fortress Biotech has a 1 year low of $1.36 and a 1 year high of $4.43. The stock has a 50-day moving average price of $1.69 and a 200 day moving average price of $1.83. The company has a market cap of $43.48 million, a P/E ratio of -0.52 and a beta of 1.75.

Insider Activity

In other Fortress Biotech news, CEO Lindsay A. Md Rosenwald bought 763,359 shares of the stock in a transaction on Monday, September 23rd. The shares were purchased at an average price of $1.84 per share, with a total value of $1,404,580.56. Following the acquisition, the chief executive officer now directly owns 3,657,264 shares of the company’s stock, valued at $6,729,365.76. This represents a 26.38 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 33.40% of the stock is currently owned by insiders.

Institutional Trading of Fortress Biotech

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Shikiar Asset Management Inc. lifted its position in shares of Fortress Biotech by 4.4% during the 3rd quarter. Shikiar Asset Management Inc. now owns 235,969 shares of the biopharmaceutical company’s stock worth $342,000 after buying an additional 10,000 shares during the period. Virtu Financial LLC acquired a new stake in shares of Fortress Biotech in the 1st quarter valued at $31,000. Integrated Wealth Concepts LLC grew its stake in shares of Fortress Biotech by 68.2% during the third quarter. Integrated Wealth Concepts LLC now owns 46,100 shares of the biopharmaceutical company’s stock worth $67,000 after purchasing an additional 18,700 shares during the period. Atria Investments Inc grew its stake in shares of Fortress Biotech by 58.4% during the third quarter. Atria Investments Inc now owns 71,484 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 26,351 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of Fortress Biotech by 28.8% during the third quarter. Geode Capital Management LLC now owns 168,607 shares of the biopharmaceutical company’s stock worth $244,000 after purchasing an additional 37,736 shares during the period. Institutional investors and hedge funds own 96.51% of the company’s stock.

Fortress Biotech Company Profile

Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.